Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]
SEC Accession No. 0001193125-26-197402
Filing Date
2026-04-30
Accepted
2026-04-30 16:20:55
Documents
14
Period of Report
2025-12-31

Document Format Files

Seq Description Document Type Size
1 10-K/A achv-20251231.htm   iXBRL 10-K/A 1678097
2 EX-10.13 achv-ex10_13.htm EX-10.13 152114
3 EX-31.1 achv-ex31_1.htm EX-31.1 12533
4 EX-31.2 achv-ex31_2.htm EX-31.2 15841
  Complete submission text file 0001193125-26-197402.txt   4562295

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT achv-20251231.xsd EX-101.SCH 1725922
18 EXTRACTED XBRL INSTANCE DOCUMENT achv-20251231_htm.xml XML 15597
Mailing Address 22722 29TH DR. SE SUITE 100 SEATTLE WA 98021
Business Address 22722 29TH DR. SE SUITE 100 SEATTLE WA 98021 425-686-1500
ACHIEVE LIFE SCIENCES, INC. (Filer) CIK: 0000949858 (see all company filings)

EIN.: 954343413 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K/A | Act: 34 | File No.: 033-80623 | Film No.: 26925784
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)